Citigroup Inc. Has $15.57 Million Stake in Haemonetics Co. (NYSE:HAE)

Citigroup Inc. trimmed its stake in Haemonetics Co. (NYSE:HAE) by 96.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 193,658 shares of the medical instruments supplier’s stock after selling 5,678,717 shares during the period. Citigroup Inc. owned about 0.38% of Haemonetics worth $15,566,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Quarry LP acquired a new stake in Haemonetics in the 2nd quarter worth $39,000. Daiwa Securities Group Inc. acquired a new stake in Haemonetics in the 2nd quarter worth $82,000. Canada Pension Plan Investment Board acquired a new stake in Haemonetics in the 2nd quarter worth $83,000. Nisa Investment Advisors LLC grew its position in Haemonetics by 124.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 632 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Haemonetics in the 2nd quarter worth $140,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HAE has been the topic of several research analyst reports. BTIG Research started coverage on shares of Haemonetics in a research report on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price target on the stock. Barrington Research reissued an “outperform” rating and issued a $108.00 target price on shares of Haemonetics in a research note on Friday, November 8th. JMP Securities reissued a “market outperform” rating and issued a $125.00 target price on shares of Haemonetics in a research note on Tuesday, August 13th. Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price on the stock in a research note on Friday, November 8th. Finally, Citigroup lowered their target price on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Price Performance

NYSE:HAE opened at $87.83 on Thursday. The firm has a market cap of $4.41 billion, a PE ratio of 36.44, a price-to-earnings-growth ratio of 1.37 and a beta of 0.32. Haemonetics Co. has a 12 month low of $70.25 and a 12 month high of $97.97. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. The company’s 50-day moving average price is $79.47 and its two-hundred day moving average price is $82.28.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The firm had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. During the same period in the previous year, the business earned $0.99 earnings per share. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. On average, equities analysts anticipate that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.